CMPD1

CMPD1 is a selective and non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor with apparent Ki (Kiapp) of 330 nM[1][2].

Product Specifications

CAS Number

[41179-33-3]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

MAPKAPK2 (MK2)

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cmpd1.html

Concentration

10mM

Purity

99.86

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=C(O)C=C1)CCCC2=CC=C(C3=CC=CC=C3F)C=C2

Molecular Formula

C22H20FNO2

Molecular Weight

349.40

Precautions

H302, H315, H319, H335

References & Citations

[1]Gurgis F, et al. Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2. Cell Death Discov. 2015 Sep 7;1:15028.|[2]Davidson W, er al. Discovery and characterization of a substrate selective p38alpha inhibitor. Biochemistry. 2004 Sep 21;43 (37) :11658-71.|[3]Phoa AF, et al. Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signalling. Biochem Pharmacol. 2015 Dec 15;98 (4) :587-601.